The COVID-19 pandemic turned Chinese vaccine maker Sinovac Biotech into a global household name after its CoronaVac jab became a billion-dollar money-spinner and one of the world's most-administered inoculations against the virus. But hidden away behind its success lies a bitter, decade-long power struggle for control of the company.
Caixin
Sinovac's COVID fortune fuels bitter boardroom battle
Power struggle traces back to 2016, with co-founders on opposite sides
China's Sinovac earned vast profits from its COVID-19 vaccine. © Reuters
Read Next
Latest on Caixin
